<DOC>
	<DOCNO>NCT01320254</DOCNO>
	<brief_summary>The purpose study determine efficacy panitumumab plus cisplatin/gemcitabine ( CisGem ) combination chemotherapy KRAS wild-type biliary tract cancer patient without systemic pre-treatment , compare historical data randomise control group without antibody , verifies historically base assumption .</brief_summary>
	<brief_title>PiCCA Study ( Panitumumab Combination With Cisplatin/Gemcitabine )</brief_title>
	<detailed_description>The rationale study assessment clinical activity Panitumumab conjunction standard Cisplatin/Gemcitabine chemotherapy patient cholangiocarcinomas gall bladder carcinoma 1st-line therapy . Cholangiocarcinoma ( CCA ) epithelial cancer originate bile duct feature cholangiocyte differentiation . CCA second common primary hepatic malignancy , epidemiologic study suggest incidence increase Western country . Hepatobiliary malignancy account 13 % 7.6 million annual cancer-related death worldwide CCA account approximately 20 % death hepatobiliary malignancy ( Kubicka Manns 2000 ; Kubicka 2004 ; Blechacz Gores 2008 ; Malek et al . 2007 ) . The curative option patient gallbladder- bile duct cancer surgical resection . Advanced CCA devastate prognosis . There limited number study systemic treatment option biliary cancer . Gallbladder bile duct carcinoma moderately chemotherapy-sensitive tumor . The objective response rate phase II study 5-FU gemcitabine monochemotherapy 10 - 30 % ( Kubicka et al . 2001b ) . Higher response rate 20 - 50 % observed phase II study combination chemotherapy , particular combination gemcitabine/cisplatin ( Kubicka 2004 ; Malek et al . 2007 ) . Recently first time improvement overall survival demonstrate large randomized phase III trial chemotherapy combination cisplatin gemcitabine ( n=206 ) compare gemcitabine mono-chemotherapy ( n=204 ) ( Valle et al . 2009 ) . Median overall survival 8,2 month monotherapy arm versus 11,7 month combination arm ( p=0.002 ) . As consequence study combination Cisplatin ( 25mg/m² d1,8 ) Gemcitabine ( 1000mg/m² d1,8 ) consider standard first line chemotherapy patient irresectable cholangio- gallbladder carcinoma . The grow understanding molecular pathogenesis CCA open new therapeutic option molecular target ( Blechacz Gores 2008 ) . In particular EGFR signal appear important tumor growth CCA . Inhibition EGFR signal show significantly suppress CCA cell growth ( Blechacz Gores 2008 ) . In addition EGFR directly activate bile acid promote CCA cell proliferation , potential explanation tropism exert CCA biliary tree . It show EGFR activation sustain CCA failure internalize ligand-receptor complex , homeostatic mechanism essential receptor inactivation . EGFR phosphorylation result activation downstream kinase p42/44 MAPK p38 MAPK , turn increase cyclooxygenase 2 expression CCA cell . Further evidence essential contribution EGFR-signalling come study IL-6 ( Blechacz Gores 2008 ) . IL-6 key cytokine pathogenesis CCA . IL-6 produce high level CCA cell , elevate IL-6 serum concentration report CCA patient . It show cross-communication IL-6 EGFR result IL-6 mediate overexpression EGFR . Recently first result randomize phase II study gemcitabine oxaliplatin ( GEMOX ) alone combination cetuximab patient advance biliary cancer report ( Malka et al . 2009 ) . The primary objective study 4-month PFS rate 60 % experimental arm cetuximab . The included patient monitor RAS B-RAF mutation . However compare GEMOX chemotherapy ( n=51 ) , GEMOX+cetuximab ( n=50 ) show increase 4-month PFS-rate ( 50 % versus 61 % ) improve median PFS ( 5 versus 7 month ) . This first evidence randomize trial anti-EGFR therapy may effective patient cholangiocarcinomas gallbladder carcinoma . KRAS downstream molecule EGFR-pathway . Recently show oncogenic RAS mutation predictive poor efficacy anti-EGFR-therapy colorectal cancer . Conversely patient colorectal cancer harbour KRAS wild-type show frequently dramatic tumor response upon anti-EGFR-treatment , indicate colorectal cancer KRAS wild type highly susceptible anti-EGFR-therapy . Although dysregulation KRAS commonly observe malignancy , mutation KRAS describe 12 % 54 % intrahepatic CCA ( Kubicka et al . 2001a ; Blechacz Gores 2008 , Gruenberger et al 2009 ) . This sharp contrast pancreatic ductal carcinoma KRAS mutation present approximately 90 % cancer . Thus , despite share developmental ontology pancreatic duct biliary tree , adult cancer different may explain negative result phase III study pancreatic cancer Cetuximab ( anti-EGFR-antibody ) . Very preliminary sparse data recent small phase II study cetuximab allow speculate whether RAS status predict response cholangiocarcinomas similarly colorectal cancer ( Gruenberger et al . 2009 ) . However , due clear evidence absence efficacy mutant KRAS colorectal cancer , presumptive population `` enrichment '' apply first trial biliary duct cancer , focus KRAS wild type patient . Since patient CCA treat large center chemotherapy protocol limited number intravenous infusion appear comfortable patient CCA . A argument investigation Cisplatin/Gemcitabine/Panitumumab randomize phase II study fact 3-week interval Cis/Gem protocol fit well 3-week interval Panitumumab schedule .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed , date informed consent start specific protocol procedure Histologically/cytologically document diagnosis cholangiocarcinoma gall bladder carcinoma At least one measurable site disease follow RECIST V. 1.1 criterion Wildtype KRAS status assess standardize PCR Unresectable , locally advanced metastatic disease Age &gt; 18 year old ECOG Performance Status 0 1 Life expectancy least 12 week Adequate bone marrow , liver ( stenting obstruction , require ) renal function ( lab . assessment within 7 day prior screen ) : Hemoglobin &gt; 10.0 g/dl Leukocyte count &gt; 3.000/mm3 ; absolute neutrophil count ( ANC ) &gt; 1.500/mm3 Platelet count 100.000/mm³ Total bilirubin &lt; 5,0 time upper limit normal ALT AST &lt; 3 x upper limit normal Alkaline phosphatase &lt; 5 x ULN PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumarin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] Serum creatinine &lt; 1.5 x upper limit normal creatinine clearance &gt; 60 ml/min Magnesium ≥ low limit normal ; calcium ≥ low limit normal The patient willing able comply protocol duration study , include hospital visit treatment schedule followup visit examination Negative pregnancy test perform within 7 day prior start treatment , willingness use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment ( adequate : oral contraceptive , intrauterine device barrier method conjunction spermicidal jelly ) KRAS mutation Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrollment History interstitial lung disease , e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . History HIV infection chronic hepatitis B Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Preexisting neuropathy &gt; grade 1 ( NCI CTCAE ) , except loss tendon reflex ( patellar tendon reflex ) Symptomatic know brain metastases.A scan confirm absence brain metastasis require Patients seizure disorder require medication ( steroids anti epileptic ) History organ allograft Patients evidence history bleed diathesis Patients undergoing renal dialysis Patients second primary cancer , except adequately treat basal skin cancer carcinoma insitu cervix Any condition unstable could jeopardize safety patient compliance study No prior anticancer chemotherapy , radiotherapy ( exclude palliative radiotherapy administer 4 week prior study entry ) , endocrine immunotherapy Investigational drug therapy outside trial within 4weeks study entry Major surgery within 4 week start study patient must recover effect major surgery Prior antiEGFR therapy Autologous bone marrow transplant stem cell rescue within 4 month study Breastfeeding patient Substance abuse , medical , psychological social condition may interfere patient 's understanding informed consent procedure , participation study evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Palliative treatment</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cisplatinum</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Vectibix</keyword>
</DOC>